← All trials
NCT06279611
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 25, 2021
- Primary completion
- Aug 31, 2024
- Completion date
- May 31, 2026
- First posted
- Feb 28, 2024
- Last posted
- Feb 28, 2024
- Enrollment
- 18
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shanghai Longyao Biotechnology Inc., Ltd.Lead sponsor
- Nanjing Medical UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.